" There are two major hurdles with the treatment of GBM with CarT. Firstly, the blood brain barrier. Secondly is having CarT work against a solid tumours. We have had hints that these seem to be mitigated.
If CHM 1101 can't solve these problems on its own then there is still the huge opportunity to combine it with IMU's CF33 and the RenovoRx CF33 Virotherapy Delivery, only problem, both are still years away from approved.
Anyway, let's hope for a great result and a positive market reaction. Based on the market depth there is hardly any resistance to be seen but we know in this crappy market sellers will jump on the first small sp increase and dump into it.
GLTA
CHM Price at posting:
2.8¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)